




RealRate

PHARMACEUTICAL 2014

Sonnet Biotherapeutics Holdings Inc
Rank 121 of 234



The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 13% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	1,713
Cost of Goods Sold	0
Intangible Assets	9,921
Liabilities, Current	5,532
Liabilities, Non-Current	399
Other Assets	2,833
Other Compr. Net Income	233
Other Expenses	8,661
Other Liabilities	2,918
Other Net Income	-706
Other Revenues	8,247
Property and Equipment	5,620
Research and Development	0
Selling, General and Administrative Expense	4,234

Output Variable	Value in 1000 USD
Assets	20,088
Liabilities	8,849
Expenses	12,895
Revenues	8,247
Stockholders Equity	11,239
Net Income	-5,353
Comprehensive Net Income	-5,236
BaseVar	25,509
ECR before LimitedLiability	133%
Economic Capital Ratio	256%